本页面由Tiger Trade Technology Pte. Ltd.提供服务

Autolus Therapeutics PLC

1.45
-0.0700-4.61%
盘后1.450.00000.00%19:34 EDT
成交量:71.70万
成交额:106.14万
市值:3.86亿
市盈率:-1.34
高:1.54
开:1.53
低:1.44
收:1.52
52周最高:2.66
52周最低:1.18
股本:2.66亿
流通股本:1.03亿
量比:0.91
换手率:0.70%
股息:- -
股息率:- -
每股收益(TTM):-1.0804
每股收益(LYR):-1.0804
净资产收益率:-120.42%
总资产收益率:-25.96%
市净率:3.55
市盈率(LYR):-1.34

数据加载中...

公司资料

公司名字:
Autolus Therapeutics PLC
交易所:
NASDAQ
成立时间:
2014
员工人数:
753
公司地址:
The Mediaworks,191 Wood Lane,White City,London,Greater London,United Kingdom
邮编:
W12 7FP
传真:
- -
简介:
Autolus Therapeutics plc于2018年2月2日在英格兰和威尔士注册成立。该公司是一家处于早期商业化阶段的生物制药公司,致力于开发用于癌症和自身免疫性疾病的下一代T细胞疗法。其主要产品AUCATZYL(obe-cel)是一种靶向CD19的嵌合抗原受体T细胞疗法,已在美国和英国获批用于治疗复发或难治性B细胞前体急性淋巴细胞白血病。

董事

名称
职位
Christian Itin
Chief Executive Officer and Director
Michael Bonney
Chairman of the Board
Cynthia Butitta
Director
Elisabeth Leiderman
Director
John Berriman
Director
Linda Bain
Director
Ravi Rao
Director
Robert Azelby
Director
Robert Iannone
Director
Ryan Richardson
Director
William Young
Director

股东

名称
职位
Christian Itin
Chief Executive Officer and Director
Christopher Vann
Chief Operating Officer and Senior Vice President
Alex Driggs
General Counsel and Senior Vice President, Legal Affairs
Alexander Swan
Chief Human Resources Officer and Senior Vice President
Christopher Williams
Chief Business Development Officer and Senior Vice President
Cintia Piccina
Senior Vice President and US Chief Commercial Officer and Country GM
Martin Pulé
Chief Scientific Officer and Senior Vice President
Matthias Will
Chief Development Officer and Senior Vice President
Miranda Neville
Chief Technology Officer and Senior Vice President
Patrick McIlvenny
Chief Accounting Officer and Senior Vice President, Finance
Robert Dolski
Chief Financial Officer and Senior Vice President